Aim: This study tests the hypothesis that salivary extracellular RNA (exRNA) biomarkers can be developed for gingivitis detection and monitoring disease regression.
| INTRODUC TI ON
Periodontal diseases are the most common inflammatory diseases in humankind (Kassebaum et al., 2017) . Gingivitis, the reversible form of the disease, is induced by the accumulation of bacterial biofilm that can be treated with professional biofilm removal and improvement in oral hygiene (Kim, Kim, & Camargo, 2013) . If left untreated, gingivitis may progress to an irreversible form-periodontitis that involves bone and attachment loss. Periodontitis can advance to the point that it induces tooth mobility and tooth loss (Kim et al., 2013) .
It may also adversely influence systemic health via cardiovascular diseases (Kim et al., 2013) , ischemic stroke (Grau et al., 2004) or cancers (Binder Gallimidi et al., 2015; Mitsuhashi et al., 2015; Rajesh, Thomas, Hegde, & Kumar, 2013) . The common risk factors for periodontitis could be divided into inherited (e.g. genetic variants), and those that are acquired (e.g. socioeconomic factors, poor oral hygiene, cigarette smoking and diabetes) (Chapple et al., 2017) .
The quest to develop salivary biomarkers for periodontal diseases has been elusive (Giannobile et al., 2009) . Despite the scientific acceptance of salivary biomarkers for the detection of gingivitis (Henskens, Van Der Velden, Veerman, & Nieuw Amerongen, 1993; Kinney et al., 2011; Lee et al., 2012; Morelli et al., 2014; Shaila, Pai, & Shetty, 2013) , the absence of definitively validated biomarkers did not allow for such technology to receive regulatory approval and translating this diagnostic test to move into clinical practice.
Presently, the gold standard for early detection and diagnosis for gingivitis includes a comprehensive periodontal exam along with clinical examination (i.e. redness, swelling or gingival bleeding) performed during dental examinations. Unfortunately, the absence of pain in gingivitis often renders individuals unaware of their pathological gingival condition, particularly if they do not have to visit the dentist regularly (Kim et al., 2013) . While very helpful, clinical parameters do not provide full information about the current status of the disease activity, patient-specific variations, do not predict non-responders for treatment therapy and those who are "at risk" for disease progression (Ebersole, Nagarajan, Akers, & Miller, 2015) . Thus, it is desirable to develop objective and scientifically credible biomarkers for early detection and monitoring of periodontal diseases, especially that many of the affected cases are left undiagnosed and untreated (Albandar & Kingman, 1999; Tomar & Asma, 2000) .
The applications of such biomarkers could be multiple. Firstly, they might be used by community at large as self-administered point-of-care (POC) tests to screen for periodontal diseases, thus making people aware of the pathology in their oral cavities and to encourage them to search for a dental care. The chairside POC devices will require minimal clinical training and resources, lead to simpler, more cost-effective and less intensive treatment (Giannobile, 2012) . Due to close proximity of saliva to periodontal tissues and its easy collection, saliva constitutes a valuable diagnostic source, specifically as its collection is easy, repeatable and can be performed by auxiliary personnel. In addition, the salivary biomarkers present an attractive tool for quantitative Results: Eight salivary exRNA biomarkers developed for gingivitis were statistically significantly changed over time, consistent with disease regression. A panel of four salivary exRNAs [SPRR1A, lnc-TET3-2:1, FAM25A, CRCT1] can detect gingivitis with a clinical performance of 0.91 area under the curve, with 71% sensitivity and 100% specificity.
Conclusions:
The clinical values of the developed salivary exRNA biomarkers are associated with gingivitis regression. They offer strong potential to be advanced for definitive validation and clinical laboratory development test.
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Clinical Relevance
Scientific rationale for the study: Presently, the gold standard for diagnosis of gingivitis includes mainly clinical examination. As a companion diagnostics, scientifically based evaluation of gingivitis would be very beneficial as it is the most prevalent inflammatory disease in humans.
Principal findings: Principles of prospective study design (PRoBE) and rigorous clinical classification of gingivitis led to the development and validation of salivary exRNA biomarkers for gingivitis detection that are associated with disease regression. Discriminatory salivary exRNA biomarkers were developed for gingivitis detection. Four salivary exRNA panels can discriminate gingivitis from healthy periodontium with a performance of 0.91 AUC, with 71% sensitivity and 100% specificity.
Practical implications: Salivary exRNA markers can be objective molecular indicators of periodontal health for disease detection as well as gingivitis regression. and qualitative objective evaluation and monitoring of gingivitis for both scientists and dentists. The use of salivary-based POCs would also enable the underserved communities an improved access to oral health programmes as well as offers the ability to identify and monitor the patients at risk (Giannobile, 2012) . Lastly, the dental, pharmaceutical and oral health care companies could use them for optimizing the pharmaceutical efficiency such as adequate selection of target patients, optimal dose selection and to assess the performance of the current active compounds in the development of their new oral hygiene products such as toothpastes, mouthwashes, etc.
This study addresses the unmet clinical need of assessing host factors as a companion diagnostics to detect gingivitis and monitor its treatment response.
| MATERIAL S AND ME THODS

| Ethics statement
The sample collection was approved by the Institutional Review Board (IRB) at the University of California at Los Angeles (UCLA) for both the discovery phase (IRB#10-000505) and the clinical stage (IRB#15-001957) of the study. Each participant had to sign the informed consent.
| Discovery phase
Based on the prospective-specimen-collection and retrospectiveblinded-evaluation (PRoBE) study design (Pepe, Feng, Janes, Bossuyt, & Potter, 2008) , saliva was collected prospectively from 750 human subjects at the UCLA School of Dentistry. The inclusion and exclusion criteria are presented in Figure 1 . Subjects were classified as healthy or gingivitis according to research and clinical criteria (Figure 1 ).
Prior to a clinical evaluation, unstimulated whole saliva was collected for every subject. Subjects were asked to avoid oral hygiene measures, eating, drinking or gum chewing at least 1 hr prior to saliva collection. All subjects rinsed with tap water (10 ml) for 30 s about 10 min prior to saliva collection and expectorated.
Clinical samples were collected into sterile tubes, lasting 5-10 min per collection (at least 5 ml of saliva), and kept on ice through the entire process. All samples were processed, around 1 hr after collection. Samples were firstly centrifuged in a refrigerated centrifuge at 2,400 × g for 15 min at 4°C, and the supernatant was 
| Pilot clinical research study
The pilot study consisted of two stages: clinical and laboratory.
| Clinical stage
For analysis of saliva samples, 30 volunteers (aged 18-65 years), diagnosed with gingivitis, were included in this study. Figure 1 presents the inclusion and exclusion criteria. The duration of this project was 7 weeks (including 1 week pretrial training "washout" period to check if there are any allergic reactions to toothpaste's ingredients) and involved the same treatment protocol for gingivitis such as brushing with toothpastes containing 1,000 p.p.m. sodium monofluorophosphate (Colgate-Palmolive Company, New York, NY, USA). Each volunteer was instructed to brush the whole mouth with a full ribbon of the toothpaste for 1 min twice daily.
The subjects expectorated and rinsed with water. Subjects returned for a clinic visit at baseline (B), 3 and 6 weeks to donate saliva samples prior to the clinical examination. The protocol for collection and processing of saliva was the same as described previously (discovery phase), but saliva was collected only in the mornings and immediately frozen at −20°C for about 3-4 hr until further analysis.
| Laboratory stage
| Validation phase
The direct saliva transcriptome analysis For the validation phase, the direct saliva transcriptome analysis (DSTA) was performed that uses cell-free saliva supernatant instead of isolated messenger RNA (mRNA) for saliva transcriptomic detection (Lee et al., 2011) . 
| Statistical analysis
Kruskal-Wallis and chi-squared tests were performed to compare markers between healthy and gingivitis groups in the discovery phase of transcriptomic analysis. In the validation phase, the analysis of variance (ANOVA) was done at a significance level of p < 0.05. In addition, the logistic regression analysis in R was used to construct the final panel of biomarkers using the "best glm" function and the best Akaike Information Criterion. A paired t test along with the 95% confidence interval (CI) was used to compare the Löe-Silness Gingival Index (GI) (Loe, 1967) and the Quigley and Hein Plaque Index (PI) (Turesky Modification) (Quigley & Hein, 1962; Turesky, Gilmore, & Glickman, 1970) scores over different time periods. Furthermore, generalized estimating equation
(GEE) models were added to show the overall trends in biomarker changes over time. Finally, inter-individual variability between two different clinical investigators was examined (the mean of each examiner's patients clinical scores at each time point). The examiners in the study followed the same patients through the investigation.
The statistical analyses were performed using R V3.1.2 (R Core
Team, 2014) and SAS V9.4 (SAS Institute Inc., Cary, NC, USA), whereas the randomization was performed using the online statistical computing web programming "Sealed envelope" (https:// sealedenvelope.com).
| RE SULTS
| Clinical outcomes
In the discovery phase, the study group consisted of 100 subjects, including 50 gingivitis subjects (22 males and 28 females) aged 26.4 ± 6.77 years, and 50 healthy individuals aged 27.1 ± 5.67 years (23 males and 27 females). The scores for the gingivitis group were 7.2 ± 1.1% for Marginal Bleeding Index (MBI) (Loe, 1967; Muhlemann & Son, 1971 ) and 2.5 ± 0.7 mm for Probing Pocket Depth (PPD) (Ramfjord, 1959) , while for the healthy group, the results were following: 2.4 ± 1.6% for MBI and 2.1 ± 0.8 mm for PPD. The participants were mainly of White origin (73%), but also Asian (17%), black or African American (10%).
The validation phase included 30 subjects (13 males and 17 females), aged 28.2 ± 7.77 years. The participants were mainly of White origin (75%), but also Asian (20%) and black or African American (5%). The average GI scores were at Screening (Scr)
1.75 ± 0.2, at B-1.814 ± 0.18, at 3 weeks-1.684 ± 0.26 and at 6 weeks-1.46 ± 0.55, while the average PI scores were following: at Scr 2.293 ± 0.44, at B-2.307 ± 0.34, at 3 weeks-2.054 ± 0.33 and at 6 weeks-1.86 ± 0.36 (Supporting Information Table S1 ). Both GI and PI showed significantly decreased scores over time due to good oral hygiene regimens implemented by brushing with toothpastes ( Figure 2 ). The GI scores improved for 60% and PI for 93.3% of subjects over the period of 6 weeks.
Due to the long-term period of the study and large time difference between performing the discovery and the validation phases, there was a change in the current protocol for the enrolment of the patients into the study between the two stages. The MBI (Loe, 1967; Muhlemann & Son, 1971 ) applied in the discovery phase, was replaced later, in the validation phase, with the more commonly used indices such as GI (Loe, 1967) and PI (Quigley & Hein, 1962; Turesky et al., 1970) for the determination of the gingivitis status. The PPD (Ramfjord, 1959) was measured in both phases of the study. In the discovery phase, PPD was used to differentiate between healthy (non-periodontal disease) (PPD < 4 mm) and gingivitis (PPD < 4 mm) from periodontitis (≥5 mm) (apart from radiographic assessment). In the validation phase, only patients with diagnosed gingivitis were included. Study subjects could not have any PPD deeper than 5 mm (except for 3rd molars) to be enrolled in the research project.
| Investigation of potential clinical evaluators bias
There were no significant inter-examiner differences between the clinical evaluators, except for time point 6 weeks, which could potentially affect the GI and PI scores (Supporting Information Figure S1 ). This is despite the fact that all examiners were initially calibrated.
| Discovery of salivary exRNA biomarker candidates for gingivitis by HTA Microarray profiling
The 25 salivary exRNA biomarker candidates were identified from a discovery cohort of randomly selected 50 gingivitis and 50 age-/ gender-matched healthy controls (Table 1 Figure S2 , Supporting Information Table S1 ). Figure 3 presents a plot with fold changes and 95% CIs for each marker at B, 3 and 6 weeks. The increase in their alteration levels compared to the initial data might be a result of the inter-individual variability in exRNA patterns.
| Logistic regression analysis
The potential clinical discriminatory power of the developed sali- 
| D ISCUSS I ON
Saliva is a complex body fluid that is composed of unique molecular constituents (proteins, DNA, RNA, etc.) that can be discriminatory for oral and systemic disease screening, detection and monitoring The basis of biomarker research success in periodontology is to develop a diagnostic method that will have a potential to favourably affect clinical decision-making, patient outcomes and health care
providers (Ghallab, 2017) . Periodontal disease is time-consuming and expensive to treat, thus prevention and early detection constitutes significant health care benefit (Ghallab, 2017) . Thus, it would be desirable to develop biomarkers for early detection and monitoring of periodontal disease and its treatment response (Giannobile et al., 2009 ). (Table 3) . F I G U R E 3 Validation of HTA 2.0 Affymetrix array profiling results by RT-qPCR. A plot presenting the fold changes and 95% confidence interval (CI) for each of 10 salivary exRNA biomarkers on the log base 2 scale for the following periods: baseline-6 weeks, 3 week-6 weeks and baseline-3 weeks F I G U R E 4 Performance of salivary exRNA biomarkers to classify gingivitis from healthy subjects with no periodontal disease (baseline-6 weeks) [4 exRNAs: SPRR1A (m1), lnc-TET3-2:1 (m2), FAM25A (m7), CRCT1 (m10)] (0.91 AUC, 71% sensitivity, 100% specificity)
acts as an epigenetic mediator (Langemeijer, Aslanyan, & Jansen, 2009) (Table 3 ).
In addition, our study also revealed five mRNA RNAs (LGALS3, GALNT10, SOX4, FAM25A and CRCT1) that are an emerging and flourishing field for non-invasive diagnostic applications.
The identification of saliva-derived mRNA in normal and cancer patients (Hu et al., 2008; Li et al., 2004 ) and other forensic applications (Juusola & Ballantyne, 2005) have opened up a new avenue for further clinical usage. According to the literature, LGALS3
(m4) can be informative on the inflammatory and bacterial nature of gingivitis due to their connectivity to the disease-related features such as its involvement in specific cellular (apoptosis,
No.
Gene symbol Gene accession Function/biological role m1 SPRR1A NONHSAT006501.2 Epidermatitis development, keratinocyte differentiation and keratinization (Gibbs et al., 1993; Stemmler et al., 2009) Assessment of the regenerative potential of injured neurons (Starkey et al., 2009) (Ragvin et al., 2010) Airway inflammation (Kuwahara et al., 2012) m7 FAM25A NM_001146157 Inflammation and infectious disease, decrease in immune response (Deloukas et al., 2004; Mauritz et al., 2010; Wang et al., 2014) m10 CRCT1 NM_019060 Linkage to oesophageal cancer (Wu, Song, Pang, & Chen, 2016) and oropharyngeal squamous cell carcinomas (Masterson et al., 2015 ) Early Alzheimer's disease-related stages (Parra-Damas et al., 2014) Promotion of tumour cell apoptosis and upregulation of the expression of apoptosis-related proteins (Wu et al., 2016) TA B L E 3 Description of functions and biological roles of validated exRNAs for gingivitis neutrophil, eosinophil and macrophage chemotaxis, etc.) and biological functions (antimicrobial activity, etc.) (Raz et al., 1991) ( Table 3) . As expected, in gingivitis due to gum inflammation, decreased levels of LGALS3 can be observed, that is concordant with our findings. In turn, alterations in SOX4 (m6) expression, induced by transforming growth factor beta, regulate T-helper type 2 (TH2) cell-driven airway inflammation (Kuwahara et al., 2012) , whereas downregulation of FAM25A (m7) (observed also in our study) indicates increased risk for inflammation and infectious diseases (Deloukas et al., 2004; Mauritz et al., 2010; Wang, Kou, Wang, Cederbaum, & Wang, 2014) . Lastly, CRCT1 (m10) is reported to be associated with early stages of Alzheimer's disease, in which transcriptome changes affecting cell signalling, inflammation and neurotransmission pathways take place before the neuropathology in brains occur. In addition, the involvement of CRCT1 in protection against infection and inflammation is currently being explored (Parra-Damas et al., 2014) (Table 3) .
Thus, the potential role of the eight validated in this study exRNAs in pathogenetic mechanisms of periodontal diseases can be explained through their biological roles and potential functions (Table 3 ).
The major advantage of the study was the use of saliva, collected in a prospective way, as a potential non-invasive diagnostic source for detection and monitoring of gingivitis. Secondly, our study was focused on long RNAs as potential salivary biomarkers of periodontal diseases, including novel finding of lncRNAs, while the current literature reports mostly on short RNAs (microRNAs) with rather unsatisfactory performance (Kagiya, 2016; Ogata et al., 2014; Schmalz et al., 2016) . Lastly, the use of DSTA method, that omits the step of RNA extraction, seems to be much more convenient and practical way of performing the experimental stage, as RNA isolation from saliva is not easy to perform and requires diligent protocol.
The main limitation of the study was the inter-individual differences in scoring of PI and GI, which suggest that a better system of clinical evaluation for gingivitis is largely needed, such as changes in expression levels of exRNA biomarkers, that can be used as companion diagnostic tool for periodontal and clinical examinations.
In addition, the same inclusion and exclusion criteria for clinical evaluation of the periodontal status (the same periodontal indices for both discovery and validation phases) are recommended to be used for the enrolment of the subjects into the project. Lastly, a comprehensive study of the variety of exRNAs and further increased sampling is needed to establish the sensitivity and specificity of the final panel of salivary exRNA biomarkers for gingivitis.
In fact, different groups have studied the exRNA composition of saliva for detection of periodontal diseases. Inflammatory mRNA markers for interferon gamma (IFNγ) and tumour necrosis factor alpha can be detected in whole saliva to monitor the status of periodontal disease in type II diabetes patients (Gomes et al., 2006) . mRNA expression of human beta defensin-1 and -2 in the gingival tissue is associated with gingivitis, aggressive and chronic periodontitis (Vardar-Sengul et al., 2007) . Also, the expression levels of Toll-like receptors (TLR)TLR2, -4, -7, -9, interferonalpha1 (IFN-α1) (Kajita et al., 2007) and MYD88 mRNAs were significantly lower in gingivitis than in severe periodontitis lesions (Ghaderi et al., 2014) . In addition, four miRNAs (hsa-miR-451, hsa-miR-223, hsa-miR-486-5p and hsa-miR-3917) were significantly overexpressed, and seven (hsa-miR-1246, hsa-miR-1260, hsa-miR-141, hsa-miR-1260b, hsa-miR-203, hsa-miR-210 and hsamiR-205) were underexpressed by > twofold in a diseased compared to healthy gingiva (Stoecklin-Wasmer et al., 2012) . In turn, Bochenek et al. (2013) 
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